jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"jofin-458Research ArticleОригинальные исследованияOriginal ResearchРЕЗИСТЕНТНОСТЬ CANDIDA SPP. К АМФОТЕРИЦИНУ В У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХResistance Candida spp. for amphotericin B in cancer patientsБагироваН. С.BagirovaN. S.

ведущий научный сотрудник лаборатории микробиологической диагностики и лечения инфекций в онкологии Российского онкологического научного центра им. Н.Н. Блохина, д.м.н.; тел.: +7-916-247-1769

nbagirova@mail.ruДмитриеваН. В.DmitrievaN. V.

заведующая лабораторией микробиологической диагностики и лечения инфекций в онкологии Российского онкологического научного центра им. Н.Н. Блохина, д.м.н., профессор; тел.: +7-985-070-75-44

prof.ndmitrieva@mail.ruРоссийский онкологический научный центр имени Н.Н. Блохина, Москва, РоссияРоссияRussian Cancer Research Center named after N.N. Blokhin, Moscow, RussiaRussian Federation201615042016812631Copyright © Багирова Н.С., Дмитриева Н.В., 20162016Багирова Н.С., Дмитриева Н.В.Bagirova N.S., Dmitrieva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/458

Нами было протестировано 253 штамма (13 видов) Candida spp. Определение МИК амфотерицина В выполняли 2 методами: эпсилометрическим методом (Е-тест, Etest®, BioMerieux, France) и на приборе Vitek2 (BioMerieux, France). В целом, резистентность выявлена у 5 штаммов (2,1%) (С. parapsilosis – 4, C. tropicalis – 1). Среди штаммов C. albicans, C. glabrata и C.krusei резистентных к амфотерицину В штаммов не обнаружено. Совпадение результатов оценки минимальной ингибирующей концентрации амфотерицина В по категориям чувствительность/резистентность при тестировании штаммов 2 методами имело место, в целом, в 98% случаев (248 из 253): 100% для видов C. albicans, C. glabrata и C. krusei, 92,2% для C. parapsilosis и 95% для C. tropicalis. Результаты нашего исследования демонстрируют низкую степень резистентности кандид к амфотерицину В, что расширяет возможности лечения инфекций, вызванных Candida spp.

We have tested 253 strains (13 species) Candida spp. Determination of the minimum inhibitory concentration of amphotericin B was performed by 2 methods: epsilometric method (Etest®, BioMerieux, France) and on the instrument the Vitek2 (BioMerieux, France). In general, resistance was detected in 5 strains (2.1%) (C. parapsilosis – 4, C. tropicalis – 1). There were no resistance to amphotericin B among strains of C. albicans, C. glabrata and C.krusei. Coincidence evaluation results of the minimum inhibitory concentration of amphotericin B for categories sensitivity/resistance when tested strains 2 methods generally occurred in 98% of cases (248 of 253): 100% for the species C. albicans, C. glabrata and C.krusei, 92.2% for C. parapsilosis and 95% for C. tropicalis. The results of our study demonstrate a low degree of resistance of Candida spp. to amphotericin B, which allows the use of the drug in a

антифунгальная чувствительностьCandida spp.амфотерицин Врезистентностьминимальная ингибирующая концентрацияЕ-тестVitek2пограничные концентрацииantifungal susceptibilityCandida spp.amphotericin Bresistanceminimum inhibitory concentrationE testVitek 2breakpointsReferencesKriengkauykiat J., J. I. Ito, S. S. Dadwai, Epidemiology and treatment approaches in management of invasive fungal infections. Review. Clinical Epidemiology 2011; 3: 175-191Marchetti O., C. Cordonnier., T. Calandra. EJC, Guidelines from the first European Conference on Infections in Leukemia: ECIL1., Eur J Cancer Suppl 2007; 5(2): 32-42Maiken Cavling Arendrup. Candida and Candidaemia. Susceptibility and Epidemiology. Dan Med J 2013; 60(11): B4698Kriengkauykiat J., J. I. Ito, S. S. Dadwai, Epidemiology and treatment approaches in management of invasive fungal infections. Review. Clinical Epidemiology 2011; 3: 175-191Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846–2856Maiken Cavling Arendrup. Candida and Candidaemia. Susceptibility and Epidemiology. Dan Med J 2013; 60(11):B4698Pfaller M.A., Shawn A. Messer, Leah N. Woosley, Ronald N. Jones, Mariana Castanheira. Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance. August 2013 Volume 51 Number 8 Journal of Clinical Microbiology p.2571–2581Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846–2856Espinel-Ingroff A., M. A. Pfaller, B. Bustamante, E. Canton, A. Fothergill, J. Fuller, G. M. Gonzalez, C. Lass-Flцrl, S. R. Lockhart, E. Martin-Mazuelos, J. F. Meis, M. S. C. Melhem, L. Ostrosky-Zeichner, T. Pelaez, M. W. Szeszs, G. St-Germain, L. X. Bonfietti, J. Guarro, J. Turnidge. Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole. Antimicrob. Agents and Chemother. April 2014, Volume 58, Number 4, p. 2006–2012Pfaller M.A., Shawn A. Messer, Leah N. Woosley, Ronald N. Jones, Mariana Castanheira. Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance. August 2013 Volume 51 Number 8 Journal of Clinical Microbiology p.2571–2581Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846–2856Espinel-Ingroff A., M. A. Pfaller, B. Bustamante, E. Canton, A. Fothergill, J. Fuller, G. M. Gonzalez, C. Lass-Flцrl, S. R. Lockhart, E. Martin-Mazuelos, J. F. Meis, M. S. C. Melhem, L. Ostrosky-Zeichner, T. Pelaez, M. W. Szeszs, G. St-Germain, L. X. Bonfietti, J. Guarro, J. Turnidge. Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole. Antimicrob. Agents and Chemother. April 2014, Volume 58, Number 4, p. 2006–2012Diekema DJ, Pfaller MA. 2012. Utility of antifungal susceptibility testing and clinical correlations, p 131. In Hall GS (ed), Interactions of yeasts, moulds, and antifungal agents: how to detect resistance. Springer, New York, NYPfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846–2856Rex JH, Pfaller MA. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982–989Diekema DJ, Pfaller MA. 2012. Utility of antifungal susceptibility testing and clinical correlations, p 131. In Hall GS (ed), Interactions of yeasts, moulds, and antifungal agents: how to detect resistance. Springer, New York, NYEuropean Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs. Version 8.0, valid from 2015-11-16. http://mic.eucast.orgRex JH, Pfaller MA. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982–989Cuenca-Estrella M., A. Gomez-Lopez, A. Alastruey-Izquierdo, L. Bernal-Martinez, I. Cuesta, M.J. Buitrago, and J.L. Rodriguez-Tudela. Comparison of the VITEK 2 Antifungal Susceptibility System with the CLSI and the EUCAST Broth Microdilution Reference methods and with the Sensititre Yeast-One and the Etest Techniques for the Detection in Vitro of Antifungal Resistance in Yeasts. J. Clin. Microbiol., May 2010, Vol. 48, No. 5, p. 1782–1786European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs. Version 8.0, valid from 2015-11-16. http://mic.eucast.orgRanque S., L. Lachaud, M. Gari-Toussaint, A. Michel-Nguyen, M. Malliй, J. Gaudart, and S. Bertout. Interlaboratory Reproducibility of Etest Amphotericin B and Caspofungin Yeast Susceptibility Testing and Comparison with the CLSI Method. J. Clin. Microbiol. 2012, 50(7):2305Cuenca-Estrella M., A. Gomez-Lopez, A. Alastruey-Izquierdo, L. Bernal-Martinez, I. Cuesta, M.J. Buitrago, and J.L. Rodriguez-Tudela. Comparison of the VITEK 2 Antifungal Susceptibility System with the CLSI and the EUCAST Broth Microdilution Reference methods and with the Sensititre Yeast-One and the Etest Techniques for the Detection in Vitro of Antifungal Resistance in Yeasts. J. Clin. Microbiol., May 2010, Vol. 48, No. 5, p. 1782–1786Pfaller MA, Messer SA, Bolmstrom A. 1998. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn. Microbiol. Infect. Dis. 32:223–227Ranque S., L. Lachaud, M. Gari-Toussaint, A. Michel-Nguyen, M. Malliй, J. Gaudart, and S. Bertout. Interlaboratory Reproducibility of Etest Amphotericin B and Caspofungin Yeast Susceptibility Testing and Comparison with the CLSI Method. J. Clin. Microbiol. 2012, 50(7):2305Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938–944Pfaller MA, Messer SA, Bolmstrom A. 1998. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn. Microbiol. Infect. Dis. 32:223–227Багирова, Н.С. Определение резистентности Candida spp. к антифунгальным препаратам системного действия эпсилометрическим методом (Е-тест) с учетом видо-специфических особенностей кандид / Н.С. Багирова, Н.В. Дмитриева // Журнал инфектологии. – 2015. – Т. 7, № 3. – С. 91–102.Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938–944Fahriye Eksi, Efgan Dogan Gayyurhan, and Iclal Balci. Research Article. In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method. Hindawi Publishing Corporation The ScientificWorld Journal Volume 2013, Article ID 236903, 6 pages http://dx.doi.org/10.1155/2013/236903Bagirova N.S., N.V. Dmitrieva. Opredelenie rezistentnosti Candida spp. k antifungal’nym preparatam sistemnogo dejstvija jepsilometricheskim metodom (E-test) s uchetom vido-specificheskih osobennostej kandid. «Zhurnal Infektologii» 2015; tom 7 №3, 91-102M. Cuenca-Estrella, D. Rodriguez, B. Almirante et al., “In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 2, pp. 194–199, 2005M. Cuenca-Estrella, D. Rodriguez, B. Almirante et al., “In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 2, pp. 194–199, 2005N. Kiraz, Z. Erturan, M. Uzun et al., “Susceptibility of 300 Candida albicans strains to amphotericin B, flucytosine, fluconazole ve mikonazole,” Klimik Dergisi, vol. 11, no. 3, pp. 116–118, 1998N. Kiraz, Z. Erturan, M. Uzun et al., “Susceptibility of 300 Candida albicans strains to amphotericin B, flucytosine, fluconazole ve mikonazole,” Klimik Dergisi, vol. 11, no. 3, pp. 116–118, 1998M. Cuenca-Estrella, L. Rodero, G. Garc´ıa-Effr´on, and J. L. Rodriguez-Tudela, “Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996–1999,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 981–987, 2002M. Cuenca-Estrella, L. Rodero, G. Garc´ıa-Effr´on, and J. L. Rodriguez-Tudela, “Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996–1999,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 981–987, 2002D. J. Diekema, S. A. Messer, A. B. Brueggemann et al., “Epidemiology of candidemia: 3-Year results from the emerging infections and the epidemiology of Iowa organisms study,” Journal of Clinical Microbiology, vol. 40, no. 4, pp. 1298–1302, 2002D. J. Diekema, S. A. Messer, A. B. Brueggemann et al., “Epidemiology of candidemia: 3-Year results from the emerging infections and the epidemiology of Iowa organisms study,” Journal of Clinical Microbiology, vol. 40, no. 4, pp. 1298–1302, 2002

The authors declare that there are no conflicts of interest present.